



### Pending Claims

U.S. Patent Application No. 09/578,453  
PHARMACEUTICAL COMPOSITIONS AND UTILIZATION THEREOF PARTICULARLY FOR THE  
TREATMENT OF NEURODEGENERATIVE DISORDERS  
Inventors: Jacques MALLET *et al.*

16. A recombinant virus selected from the group consisting of adenovirus, adeno-associated virus and herpes virus, said recombinant virus comprising a nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration *in vitro*.
17. A recombinant virus according to claim 16, wherein said virus is an adenovirus.
18. A recombinant virus according to claim 16, wherein the nucleic acid comprises SEQ ID No. 2 or an active variant thereof.
19. A recombinant virus according to claim 16, wherein said virus further comprises a second nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration.
20. A recombinant virus according to claim 16, wherein said virus is a replication defective virus.
21. A recombinant virus according to claim 16, wherein the nucleic acid encodes the p53Val135 mutated form of p53.
22. A method of inhibiting toxicity in cultured neuronal cells comprising administering to said cells a nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration *in vitro*.

25. The method according to claim 22, wherein the nucleic acid is within a vector.
26. The method according to claim 25, wherein the vector is a replication defective virus.